CTXR · NASDAQ
Citius Pharmaceuticals (CTXR) Stock Price & Fundamentals
Citius Pharmaceuticals (CTXR) closed at $630.12 on Oct 9, 2026, down 1.08% from the previous close of $636.97.
Share price, past year
1Y +0.28%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $630.12 |
| Sep 30, 2026 | $631.90 |
| Aug 31, 2026 | $578.85 |
| Jul 31, 2026 | $543.18 |
| Jun 30, 2026 | $524.26 |
| May 29, 2026 | $511.63 |
| Apr 30, 2026 | $512.50 |
| Mar 31, 2026 | $538.95 |
| Feb 27, 2026 | $562.74 |
| Jan 30, 2026 | $577.35 |
| Dec 31, 2025 | $592.34 |
| Nov 28, 2025 | $604.10 |
| Oct 31, 2025 | $621.00 |
Key statistics
- Market cap
- $17.30B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.68
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 27.5M
- Dividend yield
- —
- 52-week range
- $501.95 – $638.76
Citius Pharmaceuticals's market cap is $17.30B, based on a share price of $630.12 and 27.5M shares outstanding as of Jun 30, 2026.
Financials
Citius Pharmaceuticals reported revenue of $90.00K for fiscal 2022, unchanged 0.00% from fiscal 2021.
Citius Pharmaceuticals reported a net loss of $32.54M in fiscal 2023.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Sep 30, 2022 | $90.00K | 0.0% | −$33.64M | −37,378.5% | −$0.23 | — |
| FY2021ended Sep 30, 2021 | $90.00K | 0.0% | −$23.05M | −25,616.0% | −$0.23 | −$24.26M |
| FY2020ended Sep 30, 2020 | $90.00K | 0.0% | −$17.55M | −19,497.9% | −$0.45 | −$16.93M |
| FY2019ended Sep 30, 2019 | $90.00K | +20.0% | −$15.56M | −17,291.3% | −$0.77 | — |
| FY2018ended Sep 30, 2018 | $75.00K | +50.0% | −$12.54M | −16,715.5% | −$1.17 | — |
| FY2017ended Sep 30, 2017 | $50.00K | — | −$10.38M | −20,769.9% | −$1.89 | −$7.97M |
| FY2013ended Sep 30, 2013 | $0.00 | — | — | — | — | — |
| FY2012ended Sep 30, 2012 | $0.00 | — | — | — | — | — |
| FY2011ended Sep 30, 2011 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2026ended Jun 30, 2026 | $1.49M | — | −$0.34 |
| Q2 FY2026ended Mar 31, 2026 | $1.67M | — | −$0.95 |
| Q1 FY2026ended Dec 31, 2025 | $3.94M | — | −$0.38 |
| Q3 FY2014ended Jun 30, 2014 | $0.00 | — | — |
| Q2 FY2014ended Mar 31, 2014 | $0.00 | — | — |
| Q4 FY2013ended Dec 31, 2013 | $0.00 | — | — |
| Q4 FY2013ended Sep 30, 2013 | $0.00 | — | — |
| Q3 FY2013ended Jun 30, 2013 | $0.00 | — | — |
Company profile
- Name
- Citius Pharmaceuticals, Inc.
- Ticker
- CTXR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016
- Incorporated in
- NV
- Fiscal year ends
- September
- SEC CIK
- 0001506251
Recent SEC filings
- Aug 21, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 5, 2026
- Jun 1, 2026
- May 15, 2026
- May 15, 2026
- May 8, 2026
Frequently asked questions
What is Citius Pharmaceuticals's stock price?
Citius Pharmaceuticals (CTXR) closed at $630.12 on Oct 9, 2026, down 1.08% from the previous close of $636.97.
What is Citius Pharmaceuticals's market cap?
Citius Pharmaceuticals's market cap is $17.30B, based on a share price of $630.12 and 27.5M shares outstanding as of Jun 30, 2026.
How much revenue does Citius Pharmaceuticals make?
Citius Pharmaceuticals reported revenue of $90.00K for fiscal 2022, unchanged 0.00% from fiscal 2021.
Sources and methodology
Fundamentals come from Citius Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures